NASDAQ:AKLI • US00974B1070
The current stock price of AKLI is 0.432 USD. Today AKLI is down by -0.62%. In the past month the price increased by 2.71%. In the past year, price decreased by -63.7%.
ChartMill assigns a technical rating of 8 / 10 to AKLI. When comparing the yearly performance of all stocks, AKLI turns out to be only a medium performer in the overall market: it outperformed 53.94% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to AKLI. The financial health of AKLI is average, but there are quite some concerns on its profitability.
On May 14, 2024 AKLI reported an EPS of -0.12 and a revenue of 383.00K. The company beat EPS expectations (15.97% surprise) and missed revenue expectations (-52.71% surprise).
6 analysts have analysed AKLI and the average price target is 0.66 USD. This implies a price increase of 53.47% is expected in the next year compared to the current price of 0.432.
For the next year, analysts expect an EPS growth of 19.97% and a revenue growth 94.59% for AKLI
Over the last trailing twelve months AKLI reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -242.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.07% | ||
| ROE | -96.7% | ||
| Debt/Equity | 0.08 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 22.39 | 30.982B | ||
| WAY | WAYSTAR HOLDING CORP | 16.1 | 5.152B | ||
| DOCS | DOXIMITY INC-CLASS A | 14.89 | 4.884B | ||
| HTFL | HEARTFLOW INC | N/A | 2.038B | ||
| CERT | CERTARA INC | 14.25 | 1.17B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.087B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 228.61 | 1.086B | ||
| SDGR | SCHRODINGER INC | N/A | 968.65M | ||
| TDOC | TELADOC HEALTH INC | N/A | 915.192M | ||
| PHR | PHREESIA INC | 18.5 | 761.463M | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 6.24 | 746.803M | ||
| HSTM | HEALTHSTREAM INC | 28.61 | 647.388M | ||
| EVH | EVOLENT HEALTH INC - A | 12.51 | 396.322M |
View all stocks in the Health Care Technology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing and commercializing technologies designed to directly target the physiology of the brain. The Company’s software-based medicine is designed to directly target brain function and is delivered through engaging consumer entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain. The Company’s products include EndeavorRx, Selective Stimulus Management Engine (SSME), Body Brain Trainer (BBT) and Spatial Navigation (SNAV) Engine. EndeavorRx product is measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. SSME is specifically engineered to target and activate the systems in the brain that play a key role in attention function.
AKILI INC
71 Commercial Street, Mailbox 312
Boston MASSACHUSETTS US
Employees: 66
Phone: 16174560597
Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing and commercializing technologies designed to directly target the physiology of the brain. The Company’s software-based medicine is designed to directly target brain function and is delivered through engaging consumer entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain. The Company’s products include EndeavorRx, Selective Stimulus Management Engine (SSME), Body Brain Trainer (BBT) and Spatial Navigation (SNAV) Engine. EndeavorRx product is measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. SSME is specifically engineered to target and activate the systems in the brain that play a key role in attention function.
The current stock price of AKLI is 0.432 USD. The price decreased by -0.62% in the last trading session.
AKLI does not pay a dividend.
AKLI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
AKILI INC (AKLI) operates in the Health Care sector and the Health Care Technology industry.
AKILI INC (AKLI) has a market capitalization of 34.01M USD. This makes AKLI a Nano Cap stock.